The Zenger Society: A Forum For Free Speech (Page 2)  Echolegacy: Thank you, Keith, for a great laugh at Trump's expense. The most telling line from the scarecrow was "Some people without a brain do a great deal of talking," which says it all. My gratitude for brightening up a dismal, rainy Sunday (its raining like hell here and the lake is rising, actually!) ECHO  KeithJ: yes lol you figured my point out Echo ,, been another bad storm system just like Easter Sunday was today here again. MJ59: Seems we're slowing down: In Australia As at 6:00am on 21 April 2020, there have been 6,625 confirmed cases of COVID-19 in Australia. There have been 13 new cases since 6:00am yesterday. Of the 6,625 confirmed cases in Australia, 71 have died and 4,258 have been reported as recovered from COVID-19. More than 434,000 tests have been conducted across Australia. (Edited by MJ59) KeithJ: yes but what is AU's death toll ,,here last i seen was 66k ,,more than the Vietnam US soldiers killed MJ59: Yep, def seems to be slowing  In Australia As at 3:00pm on 21 April 2020, there have been 6,645 confirmed cases of COVID-19 in Australia. There have been 26 new cases since 3:00pm yesterday. Of the 6,645 confirmed cases in Australia, 71 have died and 4,291 have been reported as recovered from COVID-19. More than 439,000 tests have been conducted across Australia. (Post deleted by OoOoOoOoOoOoOoOoOoO ) MJ59: Mesoblast treatment achieves "remarkable" results for critical Covid-19 patients 24 April 2020, Written by Matt Ogg Mesoblast treatment achieves "remarkable" results for critical Covid-19 patients An Australian-developed stem cell treatment has drastically increased survival rates in trials for ventilator-dependent patients suffering from acute respiratory distress syndrome (ARDS) due to Covid-19. Melbourne-based regenerative medicine company Mesoblast (ASX: MSB, NASDAQ: MESO) has been engaged in trials with New York City's Mt Sinai hospital to intravenously infuse its product remestemcel-L in patients, and the early signs are promising. The sample size of 12 patients may be small, but 83 per cent (10) of them have survived after the stem cell treatment compared to a 12 per cent survival rate for ventilator-dependent Covid-19 patients with the condition at a major referral hospital network in the city. Mesoblast reports 75 per cent of the patients (nine) were able to come off ventilator support within a median of 10 days, compared to a 9 per cent rate for patients treated with standard of care during March and April. Seven of the patients, who were given remestemcel-L within five days under emergency compassionate use, have been discharged from the hospital. Using bone marrow aspirate from healthy donors, Mesoblast's proprietary technology is currently used to treat a condition called acute graft versus host disease (aGVHD), which many suffer after receiving a bone marrow transplant (BMT). But as the Covid-19 pandemic took centre stage, the company hypothesised Remestemcel-L would be able to treat what is known as a cytokine storm - a kind of hyperinflammatory syndrome - in the lungs that often occurs with serious Covid-19 cases. The company then quickly mobilised plans for trials in the US, Australia, China and Europe. "The remarkable clinical outcomes in these critically ill patients continue to underscore the potential benefits of remestemcel-L as an anti-inflammatory agent in cytokine release syndromes associated with high mortality, including acute graft versus host disease and Covid-19 ARDS," says Mesoblast chief executive Dr Silviu Itescu. "We intend to rapidly complete the randomized, placebo-controlled Phase 2/3 trial in COVID-19 ARDS patients to rigorously confirm that remestemcel-L improves survival in these critically ill patients. The company's chief medical officer Dr Fred Grossman emphasises a significant need to improve the "dismal survival outcomes in COVID-19 patients who progress to ARDS and require ventilators". "We have implemented robust statistical analyses in our Phase 2/3 trial as recommended by the US Food and Drug Administration (FDA) in order to maximise our ability to evaluate whether remestemcel-L provides a survival benefit in moderate/severe COVID19 ARDS," he says. https://www.businessnewsaus.com.au/articles/mesoblast-treatment-achieves--remarkable--results-for-critical-covid-19-patients.html (Post deleted by staff ) (Post deleted by Echolegacy ) (Post deleted by staff ) (Post deleted by staff ) (Post deleted by staff ) (Post deleted by staff ) (Post deleted by staff ) (Post deleted by staff ) Echolegacy: Until I find a way to block dihctatr permanently, I have no problem deleting the garbage she posts. Her life must be barren as hell if this has become her primary obsession. (Edited by Echolegacy) | Politics Chat Room 39 People Chatting Similar Conversations |
